Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms, Castration-Resistant × Radium-223 × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15 Neoplasm Metastasis 2 Prostatic Neoplasms, Castration-Resistant 1 Pain 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-resistant Prostate Cancer 1 Fatigue 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1

Interventions

enzalutamide 19 Abiraterone Acetate 10 Prednisone 6 radium Ra 223 dichloride 5 darolutamide 5 abiraterone 5 Docetaxel 5 apalutamide 3 niraparib 2 cabazitaxel 2 zimberelimab 1 xentuzumab 1 tasquinimod 1 sacituzumab govitecan 1 sabizabulin 1 quemliclustat 1 pembrolizumab 1 olaparib 1 gedatolisib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 atezolizumab 1 TVB-2640 1 Standard of Care 1 Rosuvastatin Calcium 1 Radium-223 1 Radiosurgery 1 Pluvicto 1 Pioglitazone 1 Omeprazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03563014 2020-05-20

BELFIGO

Bayer

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡